FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 548 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers April 25, 2019 Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... June 15, 2022 Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem November 2, 2022 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 Load more HOT NEWS Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... ESMO Breast Cancer Virtual Congress 2021, 5-8 May Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy
